Heavy menstrual bleeding progestin treatment in bleeding disorders study
Active Project Grant Awarded Last action
- Award ID
- R01HL173767
- Recipient
-
Oregon Health & Science University UEI NPSNT86JKN51
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,973,707
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date 57% complete
- Place of performance
- Portland, OR 97239, USA
Award details come from USAspending.gov.
Description
- Abstract
- Heavy menstrual bleeding (HMB) is common among adolescents and young adults with a heritable bleeding disorder (BD) and negatively impacts health-related quality of life and physical and mental health status. Effective treatment options are available that decrease bleeding and improve quality of life, but were not studied in those with BD, so we do not know if there is similar effectiveness in this condition. We also do not know the impact of treatment on diagnostic testing for BD or on improvement of iron deficiency. Given these gaps in knowledge, the primary objective of the heavy menstrual bleeding progestin treatment in bleeding disorders study is to conduct a multicenter prospective pragmatic trial, enrolling adolescents and young adults with HMB cared for at collaborating multi-disciplinary menstrual clinic sites nationally who are choosing to initiate hormonal menstrual suppression with a progestin treatment option (N=300). In aim 1, we will compare outcomes related to (a) bleeding management, (B) quality of life, and (C) repletion of iron storage levels after six months of treatment with either 52 MG levonorgestrel-releasing intrauterine system (LNG-IUD) or oral norethindrone acetate 5 MG daily (NETA) in those with a diagnosed heritable BD. The primary outcome will be treatment success with a pictorial blood loss assessment chart (PBAC) score
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $538,341 | |
| Amendment | $524,372 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $455,497 | |
| Original award | $455,497 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Childrens Mercy Hospital | $64,500 | |
| University Of Washington | $173,354 | |
| Washington Institute For Coagulation | $119,722 |
Quick answers
Who received award R01HL173767?
R01HL173767 was awarded to Oregon Health & Science University by National Heart Lung and Blood Institute (National Institutes of Health) on September 15, 2024.
How much is award R01HL173767 worth?
$1,973,707 has been obligated on R01HL173767.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award